IL272845B2 - Compounds and preparations for inhibiting IRE1 - Google Patents

Compounds and preparations for inhibiting IRE1

Info

Publication number
IL272845B2
IL272845B2 IL272845A IL27284520A IL272845B2 IL 272845 B2 IL272845 B2 IL 272845B2 IL 272845 A IL272845 A IL 272845A IL 27284520 A IL27284520 A IL 27284520A IL 272845 B2 IL272845 B2 IL 272845B2
Authority
IL
Israel
Prior art keywords
amino
pyrazin
imidazo
naphthalen
cyclohex
Prior art date
Application number
IL272845A
Other languages
English (en)
Hebrew (he)
Other versions
IL272845B1 (en
IL272845A (en
Original Assignee
Optikira Llc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optikira Llc, Univ California filed Critical Optikira Llc
Publication of IL272845A publication Critical patent/IL272845A/en
Publication of IL272845B1 publication Critical patent/IL272845B1/en
Publication of IL272845B2 publication Critical patent/IL272845B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL272845A 2017-09-01 2018-08-31 Compounds and preparations for inhibiting IRE1 IL272845B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762553320P 2017-09-01 2017-09-01
PCT/US2018/049081 WO2019046711A2 (en) 2017-09-01 2018-08-31 COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1

Publications (3)

Publication Number Publication Date
IL272845A IL272845A (en) 2020-04-30
IL272845B1 IL272845B1 (en) 2023-08-01
IL272845B2 true IL272845B2 (en) 2023-12-01

Family

ID=65526075

Family Applications (1)

Application Number Title Priority Date Filing Date
IL272845A IL272845B2 (en) 2017-09-01 2018-08-31 Compounds and preparations for inhibiting IRE1

Country Status (13)

Country Link
US (1) US11649237B2 (enExample)
EP (1) EP3675858B1 (enExample)
JP (1) JP2020532589A (enExample)
KR (1) KR20200066301A (enExample)
CN (1) CN111526877B (enExample)
AU (1) AU2018326721B2 (enExample)
BR (1) BR112020004226A2 (enExample)
CA (1) CA3074139A1 (enExample)
IL (1) IL272845B2 (enExample)
MX (1) MX2020002322A (enExample)
SG (1) SG11202001609RA (enExample)
WO (1) WO2019046711A2 (enExample)
ZA (1) ZA202001320B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7444458B2 (ja) * 2018-09-21 2024-03-06 学校法人福岡大学 プリオン病治療薬
US20220194945A1 (en) * 2019-02-27 2022-06-23 Optikira, LLC Imidazolopyridine Compounds For IRE1 Inhibition
SG11202109194UA (en) * 2019-02-27 2021-09-29 Optikira Llc Pyrazolopyridine compounds for ire1 inhibition
CA3188602A1 (en) * 2020-08-07 2022-02-10 Richard Keenan Pyrazolopyridine compounds and methods of inhibiting ire1 using same
KR20230118855A (ko) * 2020-11-13 2023-08-14 더 리전츠 오브 더 유니버시티 오브 캘리포니아 IRE1α 억제제 및 이의 용도
WO2023131677A1 (en) * 2022-01-07 2023-07-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds containing a hydroxyphenyl moiety and their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064993A2 (en) * 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
US8980899B2 (en) * 2009-10-16 2015-03-17 The Regents Of The University Of California Methods of inhibiting Ire1
MX2012011504A (es) * 2010-04-05 2013-01-18 Mannkind Corp Inhibidores de enzima 1 dependiente de inositol (ire-1 alfa).
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
AU2017228398A1 (en) * 2016-03-03 2018-10-18 Cornell University Small molecule IRE1-alpha inhibitors
WO2018102751A1 (en) 2016-12-02 2018-06-07 Quentis Therapeutics, Inc. Ire1 small molecule inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007064993A2 (en) * 2005-12-02 2007-06-07 Osi Pharmaceuticals, Inc. Bicyclic protein kinase inhibitors
WO2014052669A1 (en) * 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
WO2016004254A1 (en) * 2014-07-01 2016-01-07 The Regents Of The University Of California Combined modulation of ire1

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GHOSH RAJARSHI ET AL,, ALLOSTERIC INHIBITION OF THE IRE1[ALPHA] RNASE PRESERVES CELL VIABILITY AND FUNCTION DURING ENDOPLASMIC RETICULUM ST, 10 July 2014 (2014-07-10) *
HANNAH C. FELDMAN ET AL,, STRUCTURAL AND FUNCTIONAL ANALYSIS OF THE ALLOSTERIC INHIBITION OF IRE1[ALPHA] WITH ATP-COMPETITIVE LIGANDS, 9 June 2016 (2016-06-09) *
LIKUN WANG ET AL,, DIVERGENT ALLOSTERIC CONTROL OF THE IRE1 ALPHA ENDORIBONUCLEASE USING KINASE INHIBITORS, 1 December 2012 (2012-12-01) *

Also Published As

Publication number Publication date
EP3675858A4 (en) 2021-03-17
WO2019046711A2 (en) 2019-03-07
JP2020532589A (ja) 2020-11-12
ZA202001320B (en) 2023-10-25
RU2020112425A3 (enExample) 2022-03-31
IL272845B1 (en) 2023-08-01
AU2018326721B2 (en) 2022-12-01
US20200354367A1 (en) 2020-11-12
BR112020004226A2 (pt) 2020-11-17
AU2018326721A1 (en) 2020-03-12
US11649237B2 (en) 2023-05-16
CA3074139A1 (en) 2019-03-07
MX2020002322A (es) 2020-10-05
EP3675858A2 (en) 2020-07-08
EP3675858B1 (en) 2023-04-26
CN111526877A (zh) 2020-08-11
RU2020112425A (ru) 2021-10-04
CN111526877B (zh) 2023-08-25
KR20200066301A (ko) 2020-06-09
SG11202001609RA (en) 2020-03-30
WO2019046711A3 (en) 2020-04-02
IL272845A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
IL272845B1 (en) Compounds and preparations for inhibiting ire1
JP2020532589A5 (enExample)
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
JP2014511869A5 (enExample)
RU2469032C2 (ru) Производные 2-(пиперидин-4-ил)-4-фенокси- или фениламинопиримидина в качестве ненуклеозидных ингибиторов обратной транскриптазы
JP2007523905A5 (enExample)
JP2007519754A5 (enExample)
JP2013517273A5 (enExample)
JP2010540462A5 (enExample)
RU2013143028A (ru) Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP2007531757A5 (enExample)
RU2017125520A (ru) Соединения, ингибирующие parg
RU2007124935A (ru) АМИНОПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ β-СЕКТРЕТАЗЫ
JP2020515575A5 (enExample)
JP2013507350A5 (enExample)
JP2010513272A5 (enExample)
HRP20220314T1 (hr) Spojevi n-((het)arilmetil)-heteroaril-karboksamida kao plazma kallikrein inhibitori
RU2006145205A (ru) Терапевтические соединения: пиридин в качестве каркаса
JP2014532640A5 (enExample)
IL196129A (en) Human protein tyrosine phosphatase inhibitors, compositions comprising such compounds and uses thereof in the preparation of medicaments for regulating angiogenesis
JP2021535134A5 (enExample)
CA2478068A1 (en) Dihydropyrazole compounds useful for treating or preventing cancer
JP2021501179A5 (enExample)
JP2012526803A5 (enExample)